Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. reports developments in AI-enabled personalized spine surgery solutions for lumbar and cervical procedures. The company designs, manufactures and markets the aprevo® technology platform, which combines customized surgical planning with patient-specific implants for spine fusion procedures sold primarily to hospitals and ambulatory surgical centers.
Carlsmed news commonly covers quarterly financial results, revenue guidance, clinical data for aprevo® personalized implants, product updates for cervical and patient-specific fixation systems such as corra™, and management presentations at healthcare and medical technology investor conferences.
Carlsmed (Nasdaq: CARL) said CEO and Chairman Mike Cordonnier will present at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans. A live webcast is available to registered participants and a replay will be posted afterward.
Carlsmed (Nasdaq: CARL) announced the first personalized cervical plating procedure using the corra™ Cervical Plating System on Feb. 18, 2026.
The procedure, performed by Dr. Aaron Clark at UCSF, begins a clinical evaluation ahead of a planned commercial launch of corra™ later in 2026 and highlights integration with aprevo® planning and interbody devices.
Carlsmed (Nasdaq: CARL) will report fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will host a conference call and concurrent webcast at 1:30 PM Pacific Time, with a replay archived on the company's website.
Carlsmed (Nasdaq: CARL) announced the first posterior lumbar spine surgery using its aprevo® Lumbar Bi-lateral Posterior System, performed Feb. 10, 2026 at University of Colorado Hospital.
The company says the procedure demonstrates aprevo® integration across lumbar fusion approaches and expects a full commercial launch later in 2026.
Carlsmed (Nasdaq: CARL) reported preliminary unaudited revenue of approximately $15.2 million for the fourth quarter of 2025, about +61% versus Q4 2024, and preliminary full year 2025 revenue of approximately $50.5 million, about +86% versus 2024. The company said it added 101 new surgeon users in 2025, a 61% increase in its surgeon user base, and launched aprevo cervical with early positive surgeon feedback. Results are preliminary, unaudited and subject to revision until the Company files its 2025 Annual Report on Form 10-K.
Carlsmed (Nasdaq: CARL) announced publication of a retrospective cohort study in Global Spine Journal showing that 3D preoperative planning plus patient-specific aprevo® interbody implants reduced 2-year mechanical-complication revision rates to 4.3% (n=115) versus 16.6% (n=997) with conventional stock implants (p<0.001), a 74% relative reduction. The comparator cohort came from the International Spine Study Group dataset of senior spine surgeons. Authors note improved restoration of distal lumbar lordosis and potential reductions in proximal junctional kyphosis, reoperations, and economic burden. The peer-reviewed article is available online in Global Spine Journal.
Carlsmed (Nasdaq: CARL) announced that Mike Cordonnier, Chairman and CEO, will present at the J.P. Morgan 2026 Healthcare Conference on Wednesday, January 14, 2026 from 4:30–5:10 PM PT in San Francisco.
Carlsmed management also said it will host one-on-one investor meetings during the conference.
Carlsmed (Nasdaq: CARL) announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion on December 3, 2025, and will present early clinical experience at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting, December 3–6, 2025.
The aprevo® Cervical Interbody System pairs AI-driven preoperative planning with 3D-printed, patient-specific implants. Carlsmed reported its first 50+ cervical cases, noting efficient workflow integration, precise implant fit with maximized endplate coverage, and an ability to achieve planned sagittal and coronal alignment versus stock implants.
Carlsmed referenced prior aprevo® lumbar results showing lower complication rates and fewer revision surgeries, cited 370,000 U.S. cervical fusions performed this year as market context, and will hold a CSRS lunch workshop on Dec 4, 2025 at 12:30 PM EST.
Carlsmed (Nasdaq: CARL) announced that Chairman and CEO Mike Cordonnier will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 from 9:00–9:25 AM ET in New York.
Management will host one-on-one investor meetings, a live webcast will be available to registered participants, and a replay will be posted at https://investors.carlsmed.com/.
Carlsmed (Nasdaq: CARL) reported Q3 2025 revenue of $13.1M, a 98% year‑over‑year increase, gross margin of 75.9%, and cash and equivalents of $115.5M as of September 30, 2025. The company raised full‑year 2025 revenue guidance to $49.0–$50.0M (≈80%–84% growth vs. 2024) and shortened aprevo implant lead times to 8 business days. CMS NTAP reimbursement for aprevo cervical procedures took effect Oct 1, 2025; commercial launch expected early 2026 and >50 cervical procedures completed in clinical evaluation. Carlsmed amended its debt facility to increase availability to $50M and extended maturity and interest‑only period.